Skip to main content

Advertisement

Log in

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

  • Original Article
  • Published:
ADHD Attention Deficit and Hyperactivity Disorders

Abstract

To examine changes in partially responsive anxiety symptoms utilizing adjunctive treatment with atomoxetine in the treatment of adult ADHD patients with comorbid partially responsive anxiety symptoms. Consenting adult patients (n = 29) with confirmed diagnosis of generalized anxiety and comorbid attention deficit hyperactivity disorder (ADHD) participated in this open-label study. All patients had significant comorbid anxiety symptoms (HAM-A > 7) and failed to respond to 8-week trials of selective serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs). All patients were treated with atomoxetine as adjunctive to SSRIs or to SNRIs and were followed for at least 12 weeks. The primary outcome measure was the Clinical Global Impression severity subscale. Other scales included the Hamilton Anxiety Scale (HAM-A), the adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist, and Sheehan’s Disability Scale. Baseline measures prior to the treatment with atomoxetine were compared to those at 4, 8, and at 12 weeks of treatment. Monitoring for pulse, blood pressure, and weight changes was carried out at baseline and at end point. Twenty-seven patients (93%) completed this open-label study. There was significant resolution of symptoms of all outcome measures, including the symptoms of anxiety, as shown by changes from baseline in HAM-A, ASRS-v1.1, and CGI at 12 weeks (P < .001). Also, there was significant reduction in the disability score at 12 weeks. Patients completed the study, tolerated the adjunctive treatment, and there were no significant cardiovascular or weight changes. Two patients withdrew from the study during the first 4 weeks of treatment due to side effects. Atomoxetine can be used as an adjunctive treatment in adult patients with ADHD and comorbid partially responsive anxiety symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Adler LA, Reingold LS, Morrill MS, Wilens TE (2006a) Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 8(5):409–415

    Article  PubMed  Google Scholar 

  • Adler L, Sutton V, Moore R, Dietrich A, Reimherr F, Sangal R, Saylor K, Secnik K, Kelsey D, Allen A (2006b) Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 26(6):648–652

    Article  PubMed  CAS  Google Scholar 

  • Adler L, Spencer T, Farone S, Kessler R, Howes M, Beiderman J, Secnik C (2006c) Validity of pilot adult ADHD self report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 18(3):145–148

    Article  PubMed  Google Scholar 

  • Adler L, Spencer T, Williams D, Moore R, Michelson D (2008a) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 12(3):248–253

    Article  PubMed  Google Scholar 

  • Adler L, Spencer T, Levine L, Ramsey J, Tamura R, Kelsey D, Ball S, Allen AJ, Biederman J (2008b) Functional outcomes in the treatment of adults with ADHD. J Atten Disord 11(6):720–727

    Article  PubMed  Google Scholar 

  • Adler L, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz P, Williams D, Kelsey D (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29(1):44–50

    Article  PubMed  CAS  Google Scholar 

  • Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J, den Boer J, Fineberg N, Knapp M, Scott J, Wittchen H (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567–596

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67(4):524–540

    Article  PubMed  Google Scholar 

  • Brown R, Amler R, Freeman W (2005) Treatment of attention deficit hyperactivity disorder: overview of evidence. Paediatrics 115:749–757

    Article  Google Scholar 

  • CADDRA: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2008) Canadian ADHD practice guidelines. CADDRA, Toronto

    Google Scholar 

  • Christman AK, Fermo JD, Markowitz JS (2004) Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24(8):1020–1036

    Article  PubMed  CAS  Google Scholar 

  • Dell’Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A (2009) Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 23(9):739–753. doi:10.2165/11314350-000000000-00000

    Article  PubMed  Google Scholar 

  • Durell T, Adler L, Leibowitz M, Rubin R, Qiao M, Hollandbeck M, Deldar A, Glaser P, Kronenberger W (2010) An 8-week, open label extension period study of atomoxetine in adults with attention–deficit/hyperactivity disorder and comorbid social anxiety disorder. J ADHD Relat Disord 3:36–52

    Google Scholar 

  • Gabriel A (2010) The mixed amphetamine salt extended release (Adderall XR, MAX–XR) as an adjunctive to SSRIs or SNRIs in the treatment of adult patients with comorbid partially responsive generalized anxiety: an open label study. ADHD Atten Def Hyp Disord 2010(2):87–92

    Article  Google Scholar 

  • Gadde K, Yonish G, Wagner HR, Foust M, Allison D (2006) Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond) 30(7):1138–1142

    Article  CAS  Google Scholar 

  • Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11(3):203–226. doi:10.2165/00148581-200911030-00005

    Article  PubMed  Google Scholar 

  • Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C (2007) Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46(9):1119–1127

    Article  PubMed  Google Scholar 

  • Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Rockville

    Google Scholar 

  • Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55

    Article  PubMed  CAS  Google Scholar 

  • Henning E, Turk C, Mennin D, Fresco D, Heimberg R (2007) Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342–349

    Article  PubMed  Google Scholar 

  • Kessler R, Brandenburg N, Lane M, Roy-Byrne P, Stang P, Stein D, Wittchen H (2005) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35:1073–1082

    Article  PubMed  Google Scholar 

  • Kessler R, Adler L, Barkley R, Biederman J, Conners C, Demler O, Faraone S, Greenhill L, Howes M, Secnik K, Spencer T, Ustun T, Walters E, Zaslavsky A (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163(4):716–723

    Article  PubMed  Google Scholar 

  • Kratochvil C, Vaughan B, Harrington M, Burke W (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4:1165–1174

    Article  PubMed  CAS  Google Scholar 

  • Kratochvil C, Newcorn J, Arnold L, Duesenberg D, Emslie G, Quintana H, Sarkis E, Wagner KD, Gao H, Michelson D, Biederman J (2005) Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44(9):915–924

    Article  PubMed  Google Scholar 

  • Matza LS, Johnston JA, Faries DE, Malley KG, Brod M (2007) Responsiveness of the adult attention-deficit/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res 16(9):1511–1520 (Epub 2007 Sep 12)

    Article  PubMed  Google Scholar 

  • McGough J, Smalley S, McCracken J, Yang M, Del’Homme M, Lynn D, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162:1621–1627

    Article  PubMed  Google Scholar 

  • McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, Grupp LA, Bakish D, Filteau MJ, Gorman C, Nemeroff CB, Kennedy SH (2005) Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 173(11):1327–1334

    Article  PubMed  Google Scholar 

  • Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120

    Article  PubMed  CAS  Google Scholar 

  • Ravindran L, Kim D, Letamendi A, Stein M (2009) A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 29(6):561–564

    Article  PubMed  CAS  Google Scholar 

  • Ruscio A, Chiu W, Roy-Byrne P, Stang P, Stein D, Wittchen H, Kessler R (2007) Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 21:662–676

    Article  PubMed  Google Scholar 

  • Schweizer E (1995) Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 18:843–857

    PubMed  CAS  Google Scholar 

  • Scott N, Ripperger-Suhler J, Rajab M, Kjar D (2010) Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 20(3):197

    Article  PubMed  Google Scholar 

  • Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33

    Google Scholar 

  • Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205–222

    Article  PubMed  CAS  Google Scholar 

  • Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5):693–695

    PubMed  CAS  Google Scholar 

  • Spencer T, Faraone S, Michelson D, Adler L, Reimherr F, Glatt S, Biederman J (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67(3):415–420

    Article  PubMed  CAS  Google Scholar 

  • Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28(11):1892–1908

    Article  PubMed  CAS  Google Scholar 

  • Van Brunt D, Johnston J, Ye W, Pohl G, O’Hara N (2006) Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm 12(3):230–238

    PubMed  Google Scholar 

  • Vaughan B, Fegert J, Kratochvil CJ (2009) Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 10(4):669–676

    Article  PubMed  CAS  Google Scholar 

  • Wade A, Despiegel N, Heldbo Reines E (2006) Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 18:83–89

    Article  PubMed  Google Scholar 

  • Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26(10):729–740

    Article  PubMed  CAS  Google Scholar 

  • Wilens T, Biederman J, Faraone S, Martelon M, Westerberg D, Spencer T (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 70:1557–1562

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adel Gabriel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabriel, A., Violato, C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. ADHD Atten Def Hyp Disord 3, 319–326 (2011). https://doi.org/10.1007/s12402-011-0063-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12402-011-0063-1

Keywords

Navigation